1-4 of 4
William D. Bradley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Mary-Ellen Taplin, Arif Hussain, Satish Shah, Neal D. Shore, William Jeffery Edenfield, Oliver A. Sartor, Luke T. Nordquist, Manish Agrawal, William Clark, David R. Wise, William K. Oh, Mark T. Fleming, James E. Butrynski, Gurkamal S. Chatta, Manojkumar Bupathi, Claudia Lebedinsky, Adrian Senderowicz, Jian Li, Gozde Colak, David Nash, Patrick Trojer, William D. Bradley, Jessica Piel, Emmanuel S. Antonarakis
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT094.
https://doi.org/10.1158/1538-7445.AM2019-CT094
Published: 01 July 2019
View article titled, Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract B31: EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin lymphoma

William D. Bradley, Chih-Chi Yuan, Feng Zhao, Christina Lee, Kaylyn E. Williamson, Shilpi Arora, Charlie Hatton, Barbara M. Bryant, Patrick Trojer
Journal: Cancer Research
Cancer Res (2016) 76 (2_Supplement): B31.
https://doi.org/10.1158/1538-7445.CHROMEPI15-B31
Published: 14 January 2016
View article titled, Abstract B31: EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin lymphoma
Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2012) 72 (4): 969–978.
https://doi.org/10.1158/0008-5472.CAN-11-1875
Published: 14 February 2012
View article titled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Open the PDF for Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (3): 779–789.
https://doi.org/10.1158/0008-5472.CAN-11-2941
Published: 31 January 2012
View article titled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Open the PDF for Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer in another window
Includes: Supplementary data